Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0LU4N
|
|||
| Former ID |
DIB014261
|
|||
| Drug Name |
EGFRvIII CAR
|
|||
| Indication | Glioblastoma multiforme [ICD-11: 2A00.0; ICD-9: 191] | Phase 1/2 | [1] | |
| Company |
Kite pharma santa monica; national cancer institute
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Epidermal growth factor receptor variant III (EGFR vIII) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01454596) CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII. U.S. National Institutes of Health. | |||
| REF 2 | EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res. 2014 Feb 15;20(4):972-84. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.